Essential thrombocythemia (ET) is a chronic myeloproliferative disorder typical of middle age. However, ET has been observed also in children and young adults [1] [2] .
Major thrombotic episodes and microvascular disturbances have been described in young ET patients, but the real risk for vascular complications has not been clearly established, and specific therapeutic approaches have been investigated [3] [4] [5] [6] [7] . In this study, we retrospectively analyzed a cohort of 76 thrombocytemic patients, younger than 40 years at diagnosis, with the following aims: (1) to evaluate thrombotic and haemorrhagic complications, (2) to specify the treatment adopted and (3) to report the outcome of the pregnancies. Median follow-up is 13.5 years (range, 1-32.5). Overall, 3 patients (4%) died (acute leukemia, non-ischemic cardiac disease, second neoplasia).
Timing and type of cytoreductive treatment was based on the discretion of the physician (Table 1) . Over the years, a progressive decrease of the use of cytoreductive therapies was observed; concomitantly, Busulfan (BU) was replaced with Interferon-alpha (IFN-alpha) and anagrelide (ANA).
Ten patients (13%) experienced one or more thrombotic events. A total of 4 arterious (transient ischemic attack, acute myocardial infarction, peripheral arterial thrombosis, stroke) and 16 venous thrombosis (12 deep vein thrombosis and 4 superficial thrombophlebitis) were recorded throughout the follow-up ( Table 2 ). At the time of the first thrombotic episode, 3 patients were on cytotoxic therapy (2 patients with BU and 1 patient with IFN-alpha) and 6 patients received an antiplatelet drug;
after the first episode, all patients started a cytoreductive therapy (3 patients with BU, 2 patients with hydroxyurea and 2 patients with IFN-alpha) but a second thrombotic episode occurred in 4 cases. The cumulative risk of thrombosis during follow-up was 7.5% at 10 years and 11.8% at 15 years.
JAK2
V617F mutational analysis was performed, as previously described 10 , in 59 patients (78%). The mutation was detected in a heterozygous status in 44% of the patients, an incidence which is inferior to that observed in cohorts of general ET patients 10, 11 . JAK2 V617F mutation correlated with higher hemoglobin and lower platelets (P<0.001) at diagnosis. Twenty-four pregnancies in 13 females were followed and 15 normal babies were delivered, with 9 abortions (37.5%) and one abruption placentae; in the other cases, delivery was uneventful. During pregnancy, IFN-alpha was administered in 3 cases (in 2 cases, in combination with aspirin) and antiplatelet therapy alone was administered in 9 cases. Treatment at conception did not significantly influenced the live birth rate (treated vs. untreated: 8/12 vs. 7/12, P=0.99). The JAK2 V617F mutation did not influenced pregnancy outcome: in 24 pregnancies the occurrence of fetal loss was comparable (mutated vs. unmutated: 3/6 vs. 6/18, P=0.6).
We report the long-term outcome of a peculiar cohort of patients, with age ranging from 18 to 40 years old, followed for a prolonged period of time (median, 13.5 years). Only one patient experienced a leukemic transformation, 16 years after diagnosis, and no patient evolved to myelofibrosis. Although is generally recognized that young age identifies patients at lower thrombotic risk, our cohort of patients presents a prevalence of thrombotic complication (13%) which is higher than that previously reported in other cohorts of young (<50 yrs) ET patients, treated with Pipobroman 5 or with hydroxyurea 3 , although our population is younger and follow-up is longer. Moreover, this prevalence was comparable to that observed in young, high risk patients treated with Anagrelide 4 and to that observed in general ET studies 12 . Median time from diagnosis to therapy was 7 months (0-171). Treatment rate remained quite high, mostly due to the high number of patients with additional cardiovascular factors and with extreme thrombocytosis (over 1000x10 9 /L). 
